CA3232623A1 - Methods of treating myelodysplastic syndromes with decitabine and cedazuridine - Google Patents
Methods of treating myelodysplastic syndromes with decitabine and cedazuridine Download PDFInfo
- Publication number
- CA3232623A1 CA3232623A1 CA3232623A CA3232623A CA3232623A1 CA 3232623 A1 CA3232623 A1 CA 3232623A1 CA 3232623 A CA3232623 A CA 3232623A CA 3232623 A CA3232623 A CA 3232623A CA 3232623 A1 CA3232623 A1 CA 3232623A1
- Authority
- CA
- Canada
- Prior art keywords
- effective amount
- decitabine
- cedazuridine
- survival
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246547P | 2021-09-21 | 2021-09-21 | |
| US63/246,547 | 2021-09-21 | ||
| PCT/US2022/076757 WO2023049731A2 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3232623A1 true CA3232623A1 (en) | 2023-03-30 |
Family
ID=85721229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3232623A Pending CA3232623A1 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000888A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4404940A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531799A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240064656A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118201622A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022348907B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232623A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003537A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202327625A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023049731A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| AU2024265282A1 (en) * | 2023-05-02 | 2025-12-18 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708264C (en) * | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| US10683552B2 (en) * | 2014-11-25 | 2020-06-16 | Presidents And Fellows Of Harvard College | Clonal haematopoiesis |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| WO2021113688A1 (en) * | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
| EP4090335A1 (en) * | 2020-01-17 | 2022-11-23 | Novartis AG | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-09-21 MX MX2024003537A patent/MX2024003537A/es unknown
- 2022-09-21 AU AU2022348907A patent/AU2022348907B2/en active Active
- 2022-09-21 US US18/693,727 patent/US20250000888A1/en active Pending
- 2022-09-21 CN CN202280073476.0A patent/CN118201622A/zh active Pending
- 2022-09-21 EP EP22873816.7A patent/EP4404940A4/en active Pending
- 2022-09-21 CA CA3232623A patent/CA3232623A1/en active Pending
- 2022-09-21 TW TW111135794A patent/TW202327625A/zh unknown
- 2022-09-21 WO PCT/US2022/076757 patent/WO2023049731A2/en not_active Ceased
- 2022-09-21 KR KR1020247010215A patent/KR20240064656A/ko active Pending
- 2022-09-21 JP JP2024517163A patent/JP2024531799A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024531799A (ja) | 2024-08-29 |
| US20250000888A1 (en) | 2025-01-02 |
| AU2022348907B2 (en) | 2026-07-16 |
| WO2023049731A2 (en) | 2023-03-30 |
| AU2022348907A1 (en) | 2024-04-11 |
| WO2023049731A3 (en) | 2023-05-04 |
| TW202327625A (zh) | 2023-07-16 |
| CN118201622A (zh) | 2024-06-14 |
| EP4404940A4 (en) | 2025-07-30 |
| MX2024003537A (es) | 2024-05-03 |
| EP4404940A2 (en) | 2024-07-31 |
| KR20240064656A (ko) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI729492B (zh) | 使用包含微脂體伊立替康(irinotecan)的組合療法治療胰臟癌的方法 | |
| US20220249528A1 (en) | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome | |
| US9532984B2 (en) | Therapeutic combination for cancer treatment | |
| RU2739992C2 (ru) | Композиции апилимода и способы их применения в лечении колоректального рака | |
| US20250000888A1 (en) | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine | |
| TWI912283B (zh) | 地西他濱及西屈嘧啶(cedazuridine)組合之固體口服劑型 | |
| US11938143B2 (en) | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | |
| WO2023201338A1 (en) | Combination therapy comprising a mat2a inhibitor and a parp inhibitor | |
| CN110392573A (zh) | 用于在血液肿瘤中的HDM2-p53相互作用抑制剂的剂量和方案 | |
| US20220168329A1 (en) | Combinatorial drug treatment of cancer | |
| JP2026083415A (ja) | 癌を処置する為の医薬組成物及びその使用方法 | |
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| HK40105549A (en) | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine | |
| WO2024118943A2 (en) | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor | |
| JP2024513260A (ja) | 骨髄癌処置のためのlsd1阻害剤の組み合わせ | |
| US20110301102A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| WO2021211890A1 (en) | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | |
| Leong et al. | Bendamustine (Treanda) for chronic lymphocytic leukemia: a brief overview | |
| WO2023177894A1 (en) | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent | |
| US11052101B2 (en) | Methods for treating cancer using purine analogs by depleting intracellular ATP | |
| HK40112908A (en) | Treatment of severe and uncomplicated malaria | |
| NZ788615B2 (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| WO2013019222A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| HK1162149A (en) | Compositions for use in treating myelodysplastic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240917 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240917 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240917 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250822 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250822 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20251128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251128 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251201 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260707 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260728 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260728 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260728 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260806 |